Health Source-linked briefing

Cavity-reduced prefusion RSV F vaccine delivers durable, broad protection

Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among children under 5 years, creating a major need for durable vaccines. The RSV fusion…

Bioworld Science Desk

Original contributor via Bioworld

| October 28, 2026 | 1 min read | Updated Oct 29, 1:00 AM

Cavity-reduced prefusion RSV F vaccine delivers durable, broad protection — Image supplied with the source report: Bioworld.

Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among children under 5 years, creating a major need for durable vaccines. The RSV fusion…

Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among children under 5 years, creating a major need for durable vaccines. The RSV fusion (F) glycoprotein exists in metastable prefusion (preF) and stable postfusion (postF…

Source disclosure

This is a source-linked briefing. Read the original report from Bioworld .